Antigenicity of rabies virus glycoprotein

Although the number of antigenic sites on the rabies virus glycoprotein that have been described regularly increases with time, no attempt has been made to carefully evaluate the relative importance of each of these sites. Here we provide a more precise description of the antigenicity of the protein in mice of the H-2d haplotype; we developed this description by using 264 newly isolated monoclonal antibodies (MAbs) and a collection of neutralization-resistant (MAR) mutants. Most of the MAbs (97%) recognized antigenic sites previously described as II and III. One minor antigenic site separated from site III by three amino acids, including a proline, was identified (minor site a). Despite their proximity, there is no overlap between site III and minor site a; i.e., site III-specific MAR mutants were neutralized by the six MAbs defining minor site a, and vice versa. One of our MAbs, 1D1, reacted with sodium dodecyl sulfate-treated glycoprotein in Western blots (immunoblots) under reducing conditions and was therefore probably directed against a linear epitope, A MAR mutant selected with this MAb was still neutralized by MAbs of other specificities. This linear epitope was called G1 (G, Gif). As a general rule, we propose to reserve the term "antigenic site" (either major or minor) for regions of the protein which are defined by several MAbs originating from different fusions and to describe regions of the protein which are defined by a single MAb as epitopes. It would be interesting to test whether the same regions of the rabies virus glycoprotein are antigenic in mice of different haplotypes or in other species.

[1]  D. Stuart,et al.  Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus , 1990, Nature.

[2]  M. Lafage,et al.  Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. , 1990, The Journal of general virology.

[3]  A. Osterhaus,et al.  Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine , 1990, Journal of virology.

[4]  P. Casali,et al.  Biological characterization of human monoclonal antibodies to rabies virus , 1990, Journal of virology.

[5]  G. Air,et al.  Epitopes on protein antigens: Misconceptions and realities , 1990, Cell.

[6]  A. Osterhaus,et al.  Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. , 1989, The Journal of general virology.

[7]  E. Celis,et al.  Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients , 1988, Journal of virology.

[8]  A. Flamand,et al.  Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence , 1988, Journal of virology.

[9]  P. Coulon,et al.  Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein , 1985, Journal of virology.

[10]  C. Smith,et al.  Antigenic variants of CVS rabies virus with altered glycosylation sites. , 1985, Virology.

[11]  T. Wiktor,et al.  Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. , 1983, The Journal of general virology.

[12]  P. Rollin,et al.  Molecular basis of rabies virus virulence. II. Identification of a site on the CVS glycoprotein associated with virulence. , 1983, The Journal of general virology.

[13]  P. Rollin,et al.  Molecular basis of rabies virus virulence. I. Selection of avirulent mutants of the CVS strain with anti-G monoclonal antibodies. , 1982, The Journal of general virology.

[14]  F. Bussereau,et al.  Reproducible plaquing system for rabies virus in CER cells. , 1982, Journal of virological methods.

[15]  H. Koprowski,et al.  Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein. , 1980, The Journal of general virology.

[16]  H. Koprowski,et al.  Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Dietzschold,et al.  Rabies virus glycoprotein. II. Biological and serological characterization , 1977, Infection and immunity.

[18]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[19]  H. Koprowski,et al.  Antigenic properties of rabies virus components. , 1973, Journal of immunology.

[20]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[21]  L. C. Havens,et al.  The Antigenic Properties of Rabies Virus , 1932 .

[22]  A. Flamand,et al.  Characterization of a new temperature-sensitive and avirulent mutant of the rabies virus. , 1989, The Journal of general virology.

[23]  B. Dietzschold,et al.  Rabies virus infection: genetic mutations and the impact on viral pathogenicity and immunity. , 1987, Contributions to microbiology and immunology.

[24]  W. Wunner,et al.  Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. , 1984, Developments in biological standardization.

[25]  C. Smith,et al.  Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.